A Test in Focus

Using targeted next-generation sequencing to identify lung tumors that may respond to targeted therapies by assessing somatic mutations simultaneously within EGFR, BRAF, KRAS, HRAS, NRAS, ALK, ERBB2 and MET and identifying rearrangements (fusions) involving ALK, ROS1, RET, and NTRK1.

By Brent Westra • December 14, 2016

Mayo Medical Laboratories now offers the following tests for Zika: MZIKP — Prenatal Zika and Dengue Virus Panel, IgM, Serum and MZIKA — Zika and Dengue Virus Panel, IgM, Serum.

By Brent Westra • September 1, 2016

Plasma ceramides are predictors of adverse cardiovascular events resulting from unstable atherosclerotic plaque. Three specific ceramides have been identified as highly linked to cardiovascular disease and insulin resistance: Cer16:0, Cer18:0, and Cer24:1. Jeff Meeusen, Ph.D., provides a video overview of this new test.

By Brent Westra • July 28, 2016

Chromosomal Microarray, Prenatal, Amniotic Fluid/Chorionic Villus Sampling is a high-resolution method for detecting copy number changes (gains or losses) across the entire genome in a single assay. Umut Aypar, Ph.D., provides a video overview of this test.

By Alyssa Frank • April 27, 2016

Cytochrome P450 2C19 (encoded by the gene CYP2C19) is a liver enzyme that participates in the activation of the anticoagulant clopidogrel (Plavix) and metabolism of other drugs, such as citalopram. As a result, Clopidrigrel may be less effective in altering platelet activity in those people, who may remain at risk for heart attack, stroke, and cardiovascular death.

By Alyssa Frank • March 31, 2016

Six new next-generation sequencing (NGS) panels for the evaluation of hereditary peripheral neuropathies are now […]

By Brent Westra • March 15, 2016

The new Gastrointestinal Pathogen Panel, PCR, Feces test is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients.

By Brent Westra • March 10, 2016

The new Cell-Free DNA Prenatal Screen is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients. This test detects common chromosome abnormalities without the risk of pregnancy loss associated with invasive prenatal procedures.

By Brent Westra • January 6, 2016

This one-hour webinar will examine Lp-PLA2 and the benefits of ordering the Lipoprotein-Associated Phospholipase A2 Activity Test (Mayo ID: PLACA) offered by Mayo Medical Laboratories.Tuesday, November 24, 2015 | 2:00 p.m. – 3:00 p.m. CST

By Brent Westra • November 17, 2015

The new Phospholipase A2 Receptor Antibodies, Serum, test is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients. This test can be used to help distinguish primary from secondary membranous nephropathy. However, it should not be used as a stand-alone test but an adjunct to other clinical information.

By Alyssa Frank • October 8, 2015

The new GRHPR Gene, Full Gene Analysis, test is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients.

By Brent Westra • September 9, 2015

The new Lipoprotein-Associated Phospholipase A2 Activity, Serum, test is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients.

By Brent Westra • July 28, 2015

The new Infliximab Quantitation with Reflex to Antibodies to Infliximab, Serum, test is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients. This test should be ordered to assess a trough level quantitation for evaluation of patients with loss of response to infliximab.

By Brent Westra • May 13, 2015